Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorHsu, C\\-H.
dc.contributor.authorDziadziuszko, R.
dc.contributor.authorGomez Abreo, D. A.
dc.contributor.authorAksoy, S.
dc.contributor.authorGil Martin, M.
dc.contributor.authorRoderburg, C.
dc.contributor.authorYen, C. J.
dc.contributor.authorArican, A.
dc.contributor.authorCassier, P.
dc.contributor.authorIm, S\\-A.
dc.contributor.authorKim, S\\-B.
dc.contributor.authorKudo, T.
dc.contributor.authorOchsenreither, S.
dc.contributor.authorSendur, M. A. N.
dc.contributor.authorYonemori, K.
dc.contributor.authorRojas, C. I.
dc.contributor.authorLiu, Q.
dc.contributor.authorKeenan, T.
dc.contributor.authorHealy, J.
dc.contributor.authorKwiatkowski, M.
dc.date.accessioned2025-10-16T15:13:01Z
dc.date.issued2024
dc.description.abstractGastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology (ESMO), Munich, GERMANY, JUN 26-29, 2024
dc.identifier.doi10.1016/j.annonc.2024.05.316
dc.identifier.otherWOS:001299993900389
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5715
dc.publisherELSEVIER
dc.sourceANNALS OF ONCOLOGY
dc.titleVibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS